November 11, 2025
Contact: Vince Ettare, PharmD Medical Science and Sales Liaison
Rx3 Compounding Pharmacy
Phone: 434-386-1755 | Email: vince@rx3pharmacy.com
Website: rx3pharmacy.com 

RX3 Compounding Pharmacy Responds to FDA Policy Shift on Women’s Hormone  Therapy 

Richmond, VA – Yesterday, the Food & Drug Administration (FDA) announced a major change in its  approach to menopausal hormone therapy, initiating the removal of “black- box” warnings from many  hormone replacement products used to treat menopause symptoms. HHS+2U.S. Food and Drug  Administration+2

At RX3 Compounding Pharmacy, we applaud this evidence-based evolution in care and stand ready to  partner with both patients and prescribers to ensure the benefits of personalized hormone therapies are  fully realized. 

Key Highlights of the FDA Announcement 

• The FDA is requesting drug manufacturers update labels on menopausal hormone therapies to remove  broad boxed warnings tied to cardiovascular disease, breast cancer and probable dementia risk.  
• The change follows a comprehensive literature review, an expert panel convened in July 2025, and  public input on the balance of benefits versus risks of hormone replacement therapy (HRT). 
• Removal of the recommendation to prescribe hormone therapy at the lowest effective dose for the  shortest duration—treatment decisions are individualized and fall within the clinical judgement of a  clinician in discussion with a patient. 
• The updated guidance places greater emphasis on timing of initiation: women who start hormone  therapy within 10 years of menopause onset (or before age 60) show markedly improved benefit-risk  profiles.  
• While some warnings remain (for example, endometrial cancer risk where estrogen is unopposed in  women with a uterus), the shift opens greater flexibility in therapeutic decision-making. 

What This Means for Patients & Prescribers 

For women experiencing menopausal symptoms including hot flashes, night sweats, sleep disruption,  genitourinary changes or bone thinning, this policy shift brings renewed hope and clarity. It allows  clinicians to engage in more nuanced, individualized discussions about hormone therapy, rather than  being constrained by a one-size-fits-all caution. For prescribers, the removal of the most severe warning  label alleviates a barrier that has long contributed to under-utilization of hormone therapies. As noted by professional groups, the previous labeling triggered significant hesitation even in appropriate candidates.  ACOG+1 

RX3 Compounding Pharmacy’s Role & Commitment 

At RX3, our mission is to provide tailored, high-quality compounding solutions and support for hormone  therapy that addresses each individual’s physiology, symptoms, and goals. In light of the FDA’s  announcement, we are positioned to assist in the following ways: 

• Personalized Formulations: We compound customized hormone combinations (e.g., bioidentical  estrogens, progesterone support, androgen adjuncts) when standard commercial products don’t meet  patient needs. 
• Prescriber Collaboration: We work closely with treating physicians, including OB/GYNs, endocrinologists, and primary care providers to translate evolving evidence into individualized therapy  plans. 
• Patient Education: We will proactively provide materials and consultations to help patients understand  the updated guidance, the benefit/risk balance, and options available under tailored hormone therapy. 
• Access & Supply Assurance: With the shift in label language, we expect more providers will consider  hormone therapy. RX3 is ready to support increased demand by ensuring validated compounding  protocols, rigorous quality assurance and timely delivery. 
• Monitoring & Follow-Up: We advocate and facilitate ongoing monitoring including hormonal labs,  symptom tracking, risk-factor review, and adjustments over time to optimize outcomes.

A New Era for Women’s Mid-Life Care 

The FDA’s decision reflects a growing recognition that hormone therapy, when appropriately timed and  personalized, can do more than merely relieve menopausal symptoms. Emerging evidence suggests  benefits for bone health, cardiovascular outcomes and cognitive decline in suitable patient populations.  JAMA Network+1 

At RX3, we believe this marks a significant turning point in women’s health care: from fear driven caution  to informed, individualized therapy. We are proud to serve as a resource and partner for both patients and  prescribers during this transition. 

About RX3 Compounding Pharmacy 

With two locations serving the Richmond metro area, Virginia at large and other states, RX3  Compounding Pharmacy is a full-service compounding pharmacy specializing in customized hormone  therapies, weight loss, men’s and women’s health, pain management, veterinary compounding and other  tailored medication solutions. Our team of pharmacists and technicians leverage advanced  compounding technologies, rigorous quality control and personalized service to meet the unique needs  of each patient. 

*Compounded medications are not subject to the FDA approval process. Risks versus benefits of any  therapy should be discussed with a licensed healthcare professional.